Platform enhances protein production in microorganisms.



Genencor granted Pfizer a nonexclusive license to technology that reportedly enhances the level of expression of secreted polypeptides in microorganisms. According to Genencor, the platform may reduce the cost of developing protein-based drugs.


“Genencor’s ability to improve the efficiency of protein production is widely applicable to many industries,” says Michael V. Arbige, Genencor’s executive vp for innovation. “As the cost of protein manufacturing has long been a potential barrier to therapeutic development in some cases, Pfizer’s use of this technology may create opportunities to develop new and more effective therapies.”








This site uses Akismet to reduce spam. Learn how your comment data is processed.